Lead Product(s): Dronabinol
Therapeutic Area: Gastroenterology Product Name: PPP-002
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Tetra BioPharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 21, 2020
Tetra will use the Adversa® technology to develop a THC-based mucoadhesive film containing its PPP-002 (Dronabinol) drug candidate for the treatment of chemotherapy-induced nausea and vomiting.
Lead Product(s): Thylakoid extract
Therapeutic Area: Gastroenterology Product Name: Undisclosed
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 15, 2020
Devonian announced that the US Patent and Trademark Office has issued a Notice of Allowance for patent titled “Thylakoid Extract Composition and Formulation for the Treatment of Inflammatory Bowel Disease" covering the use of Thykamine™ for the treatment of Ulcerative Colitis.